ATP-Dependent 6-Phosphofructokinase (Nonspecified Subtype): A Promising Drug Target and Biomarker

Target Name: ATP-dependent 6-phosphofructokinase

NCBI ID: P11337

ATP-dependent 6-phosphofructokinase

Other Name(s): Phosphohexokinase | Phosphofructo-1-kinase | 6-Phosphofructokinase

ATP-Dependent 6-Phosphofructokinase (Nonspecified Subtype): A Promising Drug Target and Biomarker

Introduction

6-Phosphofructokinase (6-PK) is an enzyme involved in the metabolism of carbohydrates, primarily Glucose. It is a critical enzyme for the catabolism of Glucose, which is the primary source of energy for the human body. The regulation of 6-PK activity is crucial for maintaining proper glucose levels and is of great interest in the development of diabetes and its related complications. The nonspecific subtype of 6-PK, ATP-dependent 6-PK, has been identified as a promising drug target and biomarker for the treatment of diabetes.

Drugs that Target 6-PK

Several drugs have been developed to target 6-PK and its activity has been shown to be associated with improved glucose control in individuals with diabetes. These drugs work by inhibiting the activity of 6-PK, which results in increased glucose uptake and storage.

1. GLP-1 Receptors

GLP-1 (Gastrin-like peptide-1) is a 21-peptide hormone that is released from the pancreatic 尾-cells and has been shown to be a powerful insulin secretagogue. GLP-1 has been shown to increase the activity of 6- PK by activating its catalytic activity. Therefore, GLP-1 can be used as a drug to treat diabetes by increasing the activity of 6-PK.

2. SGLT2 Inhibitors

Sodium-glucose cotransporter 2 (SGLT2) is a protein that is expressed in the kidney and is responsible for reabsorbing glucose from the urine. SGLT2 inhibitors have been shown to increase the activity of 6-PK by inhibiting its catalytic activity. These drugs have been shown to be effective in reducing the urine output and improving the glucose control in individuals with diabetes.

3. 尾-Hydroxy-尾-Mannoside Inhibitors

尾-hydroxy-尾-mannoside (BHBM) is a carbohydrate that has been shown to interact with 6-PK and inhibits its catalytic activity. 尾HBM inhibitors have been shown to be effective in reducing the glucose uptake and storage in individuals with diabetes.

Biomarkers for 6-PK

6-PK is involved in the metabolism of many carbohydrates and its activity can be measured by several biomarkers. 1H-NMR spectroscopy is a non-invasive technique that is used to measure the activity of 6-PK. It is a powerful tool that can be used to monitor the activity of 6-PK in individuals with diabetes.

6-PK has also been shown to be involved in the regulation of insulin sensitivity. It has been shown that 6-PK activity is decreased in individuals with type 2 diabetes, and that increasing 6-PK activity can improve insulin sensitivity. Therefore, measuring 6-PK activity is a promising biomarker for the development of new diabetes treatments.

Conclusion

ATP-dependent 6-Phosphofructokinase (nonspecific subtype) is an enzyme that plays a crucial role in the metabolism of carbohydrates and is involved in the regulation of glucose levels. The nonspecific subtype of 6-PK, ATP-dependent 6-PK, has been identified as a promising drug target and biomarker for the treatment of diabetes. Drugs that target 6-PK, such as GLP-1 receptors, SGLT2 inhibitors, and 尾-hydroxy-尾-mannoside inhibitors, have been shown to be effective in improving glucose control in individuals with diabetes. Additionally, biomarkers such as 1H-NMR spectroscopy have been shown to be promising tools for measuring the activity of

Protein Name: ATP-dependent 6-phosphofructokinase (nonspecified Subtype)

The "ATP-dependent 6-phosphofructokinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP-dependent 6-phosphofructokinase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets